<ul><li>Capstan Medical Inc. has raised $110 million in a Series C round, bringing its total funding to over $150 million.</li><li>The company is developing a robotic platform and catheter-delivered heart implants for mitral and tricuspid valve replacements.</li><li>Capstan Medical plans to conduct its first in-human mitral valve procedure by early next year and tricuspid valve procedure in 2025.</li><li>Eclipse, Yu Galaxy, Intuitive Ventures, and Gideon Strategic Partners participated in the Series C round.</li></ul>

Capstan Medical raises $110M ahead of heart robot’s first-in-human procedure

Discover more